Background: Previous studies, dating back to the 1960s disclosed a progressive increase in multiple sclerosis (MS) incidence and prevalence in the Province of Padua. To further analyze whether this trend is the effect of the improved diagnostic procedures or is primarily related to a real increase risk of MS, we analyzed MS incidence and prevalence of the 5-year period 2011–2015. Methods: Patients with a diagnosis of MS or clinically isolated syndrome highly suggestive of MS were included in the study. All available sources of clinical and administrative information were evaluated. Mean annual incidence in the 5-year period 2011–2015 and the prevalence on December 31, 2015 were calculated. Results: The 2011–2015 mean incidence was 6.5/100,000/year, 7.9 for females, 4.1 for males. The overall prevalence was 182/100,000, 241 for females, 116 for males. Compared to the 2000–2009 period, mean age at onset, onset-diagnosis delay and F/M ratio did not significantly change. Since the 1960s, incidence and prevalence of MS linearly increased with no interposed plateau periods. Conclusions: MS incidence and prevalence further and significantly increased in the period 2011–2015. Our 1965–2015 data indicate a real increased risk of MS and stress a role of exogenous factors in MS susceptibility.

Keywords:
Multiple sclerosis, Incidence, Prevalence, Padua, Veneto region
1.
Rosati G: The prevalence of multiple sclerosis in the world: an update. Neurol Sci 2001; 22: 117–139.
2.
Battaglia MA, Bezzini D: Estimated prevalence of multiple sclerosis in Italy in 2015. Neurol Sci 2017; 38: 473–479.
3.
Tavolato BF: Multiple sclerosis in the Padova province (Italy). An epidemiological survey. Acta Neurol Scand 1974; 50: 76–90.
4.
Ranzato F, Perini P, Tzintzeva E, et al: Increasing frequency of multiple sclerosis in Padova, Italy: a 30 year epidemiological survey. Mult Scler 2003; 9: 387–392.
5.
Puthenparampil M, Seppi D, Rinaldi F, et al: Increased incidence of multiple sclerosis in the Veneto region, Italy. Mult Scler 2013; 19: 601–604.
6.
Polman CH, Reingold SC, Edan G, et al: Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann Neurol 2005; 58: 840–846.
7.
Thompson AJ, Banwell BL, Barkhof F, et al: Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018 Feb; 17: 162–173.
8.
McDonald WI, Compston A, Edan G, et al: Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–127.
9.
Bargagli AM, Colais P, Agabiti N, et al: Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems. J Neurol 2016; 263: 751–759.
10.
Bellantonio P, Iuliano G, Di Blasio F, et al: Prevalence and incidence of multiple sclerosis in Campobasso (Molise region chieftown, southern Italy). Clin Neurol Neurosurg 2013; 115: 1806–1808.
11.
Dell’Avvento S, Sotgiu MA, Manca S, et al: Epidemiology of multiple sclerosis in the pediatric population of Sardinia, Italy. Eur J Pediatr 2016; 175: 19–29.
12.
Nicoletti A, Patti F, Lo Fermo S, et al: Increasing frequency of multiple sclerosis in Catania, Sicily: a 30-year survey. Mult Scler 2011; 17: 273–280.
13.
Grytten N, Torkildsen O, Myhr KM: Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades. Acta Neurol Scand 2015; 132: 29–36.
14.
Pugliatti M, Rosati G, Carton H, et al: The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006; 13: 700–722.
15.
Howard J, Trevick S, Younger DS: Epidemiology of multiple sclerosis. Neurol clin 2016; 34: 919–939.
16.
Dilokthornsakul P, Valuck RJ, Nair KV, et al: Multiple sclerosis prevalence in the United States commercially insured population. Neurology 2016; 86: 1014–1021.
17.
Kingwell E, Zhu F, Marrie RA, et al: High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991–2010). J Neurol 2015; 262: 2352–2363.
18.
Aljumah M, Alroughani R, Alsharoqi I, et al: Future of management of multiple sclerosis in the middle east: a consensus view from specialists in ten countries. Mult Scler Int 2013; 2013: 952321.
19.
Sahraian MA, Pakdaman H, Harandi AA: Is it time to revise the classification of geographical distribution of multiple sclerosis? Iran J Neurol 2012; 11: 77–78.
20.
Sahraian MA, Sahebkar M, Dehghani R, et al: Multiple sclerosis-A disease on a dramatically rising trend in Iran: review of possible reasons. Iran J Neurol 2017; 16: 34–40.
21.
Eskandarieh S, Heydarpour P, Minagar A, et al: Multiple sclerosis epidemiology in East Asia, South East Asia and South Asia: a systematic review. Neuroepidemiology 2016; 46: 209–212.
22.
Bjornevik K, Riise T, Casetta I, et al: Sun exposure and multiple sclerosis risk in Norway and Italy: the EnvIMS study. Mult Scler 2014; 20: 1042–1049.
23.
Kampman MT, Brustad M: Vitamin D: a Candidate for the environmental effect in multiple sclerosis – observations from Norway. Neuroepidemiology 2008; 30: 140–146.
24.
Kampman MT, Wilsgaard T, Mellgren SI: Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J Neurol 2007; 254: 471–477.
25.
Baarnhielm M, Olsson T, Alfredsson L: Fatty fish intake is associated with decreased occurrence of multiple sclerosis. Mult Scler 2014; 20: 726–732.
26.
Wesnes K, Riise T, Casetta I, et al: Body size and the risk of multiple sclerosis in Norway and Italy: the EnvIMS study. Mult Scler 2015; 21: 388–395.
27.
Hedstrom AK, Olsson T, Alfredsson L: High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult Scler 2012; 18: 1334–1336.
28.
Munger KL, Chitnis T, Ascherio A: Body size and risk of MS in two cohorts of US women. Neurology 2009; 73: 1543–1550.
29.
Jons D, Sundstrom P, Andersen O: Targeting Epstein-Barr virus infection as an intervention against multiple sclerosis. Acta Neurol Scand 2015; 131: 69–79.
30.
Simpson S Jr, Taylor B, Burrows J, et al: EBV & HHV6 reactivation is infrequent and not associated with MS clinical course. Acta Neurol Scand 2014; 130: 328–337.
31.
Kvistad S, Myhr KM, Holmoy T, et al: Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. Mult Scler 2014; 20: 1833–1840.
32.
Riise T, Nortvedt MW, Ascherio A: Smoking is a risk factor for multiple sclerosis. Neurology 2003; 61: 1122–1124.
33.
Gustavsen MW, Page CM, Moen SM, et al: Environmental exposures and the risk of multiple sclerosis investigated in a Norwegian case-control study. BMC Neurol 2014; 14: 196.
34.
Salzer J, Hallmans G, Nystrom M, et al: Smoking as a risk factor for multiple sclerosis. Mult Scler 2013; 19: 1022–1027.
35.
Oikonen M, Laaksonen M, Laippala P, et al: Ambient air quality and occurrence of multiple sclerosis relapse. Neuroepidemiology 2003; 22: 95–99.
36.
Angelici L, Piola M, Cavalleri T, et al: Effects of particulate matter exposure on multiple sclerosis hospital admission in Lombardy region, Italy. Environ Res 2016; 145: 68–73.
37.
Heydarpour P, Amini H, Khoshkish S, et al: Potential impact of air pollution on multiple sclerosis in Tehran, Iran. Neuroepidemiology 2014; 43: 233–238.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.